☆ 4.8 Meeting Abstract

A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER plus ) advanced breast cancer (ABC) who had progressed after endocrine therapy (ET)

CANCER RESEARCH (2020)

Get Full Text
Add to Collection

Journal

CANCER RESEARCH
Volume 80, Issue 4, Pages -

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1538-7445.SABCS19-PD7-09

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.